A scoring system to assess the application of clinical trial results to individual patients Randomized controlled trials (RCTs) are the cornerstone of modern evidence-based medicine and constitute the most robust means of evaluating whether a treatment improves health. Evaluating the applicability of a clinical trial to a specific patient is a different story and is challenging: it is a difficult job for the clinician to judge whether an individual patient is similar enough to those who benefited in a clinical trial for the results to be applicable. This may constitute one of the reasons for the poor implementation of recommended guidelines in daily clinical activity. 1 A novel framework, the Trial Score, was created to assess the similarity of the participants in an RCT (such as those enrolled in the SPRINT trial 2 ) and individual patients. The approach is rooted in calculating the distance in the mathematical sense -Euclidian distance -between a hypothetical average participant in a RCT and a patient who might be considered for treatment based on that RCT's results. Emphasis on making the score very easy to use would be a logical next step, in addition to vetting whether this can be extended successfully to other clinical trials.
Air pollution and proprotein convertase subtilisin/kexin type 9
Proprotein convertase subtilisin/kexin type 9 (PCSK-9) has been related to a large number of cardiovascular risk factors, for example, atherogenic lipoproteins, arterial stiffness and platelet activation. Exposure to airborne particulate matter has been consistently associated with early death and increased morbidity, particularly raising the risk of left ventricular damage 3 and consequently cardiovascular disease (CVD). 4, 5 In 500 obese individuals, the exposure to particulate matter less than 10 mm in diameter was associated with elevated PCSK-9 circulating levels. Both experimental and epidemiological data have proved obesity is a well-known cardiovascular risk factor, 6 able to modify the effects of particulate matter exposure on heart rate variability, markers of inflammation, oxidative stress and acute phase response. Interestingly, in a multivariable linear regression model, this association was observed only for carriers of lower concentrations of interferon-gamma (IFN-g). It is here hypothesized that the observed findings can be due to the role of IFN-g in modulating numerous biological responses (e.g. systemic inflammation), further affecting cardiovascular risk.
Relationship between parity and maternal CVD risk
A dose-response meta-analysis assessed the association between parity and maternal CVD risk. 10 prospective cohort studies performed from 1987 to 2018 were included and found a potential non-linear J-shaped dose-response relationship between them. Thus, it was concluded that the risk of CVD increased by 14% among parous women compared with nulliparous women, and an increasing number of parity was associated with a non-linearly increased CVD risk. During the process of pregnancy and delivery, several substantial physiological changes in lipid, glucose levels and weight may affect multiple cardio-metabolic traits and pathways and increase the risk of CVD and coronary heart disease in later life. 7 Furthermore fluctuations of serum sex hormone levels, the change in functional vascular properties, heart rate, blood volume, perinatal haemodynamic changes and other gestational factors may play a role. 8 Community screening for heart failure with preserved ejection fraction For the patient the ability to successfully contract the left ventricle is relatively insignificant: what matters are the symptoms, often impairing day-to-day life as much as for patients with significantly reduced and with preserved left ventricular (HFpEF) contractility. Particularly in the latter group, which has a somewhat different aetiological profile, the symptoms are significantly related to age and multimorbidity. Thus, the problem of heart failure symptoms may be even more cumbersome, as HFpEF patients have been shown to have poor quality of life, 9 and constitutes a challenge, particularly in the primary care setting. 10 A potentially useful sex-specific tool for the establishment of working diagnosis of HFpEF in a general population in a community setting is presented. The tool was designed to facilitate the decision-making process in primary care units based on clinical findings: it performed moderately and similarly well both in men (c-statistics range 0.60-0.75) and in women (c-statistics range 0.51-0.76) and the performance improved significantly following the addition of N-terminal pro B-type natriuretic peptide. A prospective larger application is needed to further test the applicability of this tool.
Patient-reported outcomes are independent predictors of one-year mortality
Studies suggest that patient-reported outcomes, such as quality of life and anxiety/depression scores, provide important prognostic information independently of traditional clinical findings and can predict future quality of life, morbidity and mortality in cardiac patients. 11, 12 This finding may be explained by both physiological and behavioural processes. 13 A study from Denmark is here demonstrating that patients reporting symptoms of anxiety, depression, poor quality of life and severe symptom distress had a two-fold greater mortality risk, even after adjustment for common cardiovascular risk factors. Mental factors have proved to be as important as or more important than traditional risk factors such as blood pressure, diabetes, exercise and cholesterol in cardiac disease development.
Electrocardiogram T-wave inversion in young athletes
The role of the electrocardiogram (ECG) in the preparticipation cardiovascular screening protocol is still a topic of passionate debate. 14, 15 The central arguments concern accuracy, cost-effectiveness and the need for more robust evidence supporting improved outcomes based on ECG screening. 16, 17 T-wave inversion (TWI) in precordial leads (V1-V4) has drawn the most attention because of common misdiagnoses and variable interpretation even among sports medicine physicians and cardiologists. An international collaboration of renowned researchers sheds light on how TWI should be interpreted in young athletes: in the study population, the biological threshold outperformed chronological aging in the categorization of 'physiological' and 'pathological' TWI. The results suggest that biological age assessment could, potentially, be used to better stratify individuals at the extremes of normality (e.g. elite athletes). Follow-up of these athletes would be desirable to uncover potential misdiagnosis.
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